Attenuation of bile acid-mediated FXR and PXR activation in patients with Crohn’s disease
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Attenuation of bile acid-mediated FXR and PXR activation in patients with Crohn’s disease
Authors
Keywords
-
Journal
Scientific Reports
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-02-05
DOI
10.1038/s41598-020-58644-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Systematic review: bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence?
- (2015) P. Pavlidis et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects
- (2015) Sarah J. Woolsey et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut
- (2015) Andrea Michielan et al. MEDIATORS OF INFLAMMATION
- Bile acid nuclear receptor FXR and digestive system diseases
- (2015) Lili Ding et al. Acta Pharmaceutica Sinica B
- Bile Acid Malabsorption Deactivates Pregnane X Receptor in Patients with Crohn’s Disease
- (2013) Junichi Iwamoto et al. INFLAMMATORY BOWEL DISEASES
- Bile Acids and Derivatives, Their Nuclear Receptors FXR, PXR and Ligands: Role in Health and Disease and Their Therapeutic Potential
- (2012) Amazia Zimber et al. Anti-Cancer Agents in Medicinal Chemistry
- Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases
- (2012) Henri Duboc et al. GUT
- Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease
- (2011) R. M. Gadaleta et al. GUT
- Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease
- (2011) Rian M. Nijmeijer et al. PLoS One
- 4β-hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans
- (2010) Ulf Diczfalusy et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Bile acid malabsorption in inflammatory bowel disease
- (2010) Martin Lenicek et al. INFLAMMATORY BOWEL DISEASES
- Systemic gut microbial modulation of bile acid metabolism in host tissue compartments
- (2010) J. R. Swann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Bile Acid Receptor FXR Is a Modulator of Intestinal Innate Immunity
- (2009) P. Vavassori et al. JOURNAL OF IMMUNOLOGY
- Bile salts of vertebrates: structural variation and possible evolutionary significance
- (2009) Alan F. Hofmann et al. JOURNAL OF LIPID RESEARCH
- Inflammatory Bowel Disease
- (2009) Clara Abraham et al. NEW ENGLAND JOURNAL OF MEDICINE
- Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease
- (2009) Carsten Gnewuch et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation
- (2008) Francesco Raimondi et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Quantitative-profiling of bile acids and their conjugates in mouse liver, bile, plasma, and urine using LC–MS/MS
- (2008) Yazen Alnouti et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Highly sensitive analysis of sterol profiles in human serum by LC-ESI-MS/MS
- (2008) Akira Honda et al. JOURNAL OF LIPID RESEARCH
- Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells
- (2007) P Martin et al. BRITISH JOURNAL OF PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now